One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...

The Europe transgenic animal model market is set for robust growth, driven by surging biotechnology investments, demand for ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Developing novel ways to refine, reduce and replace the use of animals in research and enhance animal and human health.

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...

Two separate research teams used base editing to make single-nucleotide changes in human embryos this month, targeting genes ...